PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Cited by (1,000)

Items 601–700 of 1,000

1. Immunotherapy in Merkel cell carcinoma: role of Avelumab
   Amruth R. Palla, Donald C. Doll · 2018 · ImmunoTargets and Therapy
2. Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials
   Rachel Bender Ignacio, Lilie L. Lin, Lakshmi N. Rajdev, Elizabeth Y. Chiao · 2018 · Journal of the National Comprehensive Cancer Network
3. Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches
   Daniela Femia, Natalie Prinzi, Andrea Anichini, Roberta Mortarini, Federico Nichetti, Francesca Corti, Martina Torchio, Giorgia Peverelli, Filippo Pagani, Andrea Maurichi et al. · 2018 · Targeted Oncology
4. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy
   Leyre Zubiri, Ian Matthew Allen, Martin S. Taylor, Amanda C. Guidon, Steven T. Chen, Sara R. Schoenfeld, Tomas G. Neilan, Meghan E. Sise, Meghan J. Mooradian, Krista M. Rubin et al. · 2019 · The Oncologist
5. Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments
   Dipesh Uprety, Thorvardur Ragnar Halfdanarson, Julian R. Molina, Konstantinos Leventakos · 2020 · Current Treatment Options in Oncology
6. Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers
   Kimberly Mayumi Komatsubara, Joanne Jeter, Richard D. Carvajal, Kim Allyson Margolin, Dirk Schadendorf, Axel Hauschild · 2017 · American Society of Clinical Oncology Educational Book
7. Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists
   Irena Druce, Karine Tawagi, Julie L. V. Shaw, Andrea Marie Ibrahim, Heather Anne Lochnan, Michael Ong · 2022 · Current Oncology
8. Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
   Doris Helbig, Sebastian Klein · 2022 · Frontiers in Oncology
9. Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia
   Adam J. Lamble, Matthew S. Dietz, Ted Laderas, Shannon K. McWeeney, Evan F. Lind · 2017 · Journal of Immunological Methods
10. Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
    NIKE Group, Marco Gallo, Valentina Guarnotta, Federica de Cicco, Manila Rubino, Antongiulio Faggiano, Annamaria Colao · 2019 · Journal of Cancer Research and Clinical Oncology
11. Nivolumab Plus Ipilimumab for Soft Tissue Sarcoma: A Single Institution Retrospective Review
    Maggie Yuxi Zhou, Nam Q. Bui, Shreyana Bolleddu, Marta Lohman, Christoph R. Becker, Kristen Nooshin Ganjoo · 2020 · Immunotherapy
12. Seeking Standards for the Detection of Merkel Cell Polyomavirus and its Clinical Significance
    Mary Eid, Jannett Nguyen, Isaac Brownell · 2017 · Journal of Investigative Dermatology
13. Radiotherapy in the Multidisciplinary Management of Merkel Cell Carcinoma
    Michael D. Green, James Alan Hayman · 2018 · Journal of the National Comprehensive Cancer Network
14. Tumor mutational burden as predictive factor of response to immunotherapy
    María González‐Cao, Santiago Viteri, Niki Karachaliou, Andrés Aguilar, Juan Jose Garcia, Rafael Rosell · 2018 · Translational Lung Cancer Research
15. S2k‐Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) – Update 2018
    Jürgen Christian Becker, Thomas Eigentler, Bernhard Frerich, Thilo Gambichler, Stephan Grabbe, Ulrike Höller, Bernhard Daniel Klumpp, Carmen Loquai, Albrecht Krause‐Bergmann, Urs D. A. Müller-Richter et al. · 2019 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
16. High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease
    Sjoerd P. F. T. Nota, Ahmad Al-Sukaini, Shalin S. Patel, Francesco Sabbatino, G. Petur Nielsen, Vikram Deshpande, Jennifer Holmes Yearley, Soldano Ferrone, Xinhui Wang, Joseph Hasbrouck Schwab · 2021 · Frontiers in Oncology
17. The Role of Programmed Death-1 in Type 1 Diabetes
    Christopher Tucker, Alexander J. Dwyer, Brian T. Fife, Tijana Martinov · 2021 · Current Diabetes Reports
18. Merkel cell carcinoma: a forty-year experience at the Peter MacCallum Cancer Centre
    Annie J. Wang, Brendan McCann, William Soon, Paolo B. De Ieso, Mathias Bressel, Andrew Hui, Margaret S.-T. Chua, David L. Kok · 2023 · BMC Cancer
19. The Role of Neoadjuvant Immunotherapy in the Management of Merkel Cell Carcinoma with Clinically Detected Regional Lymph Node Metastasis
    Jenny H. Chang, Daphne B. Remulla, Chase J. Wehrle, Kimberly P. Woo, Fadi S. Dahdaleh, Daniel Joyce, Samer A. Naffouje · 2024 · Annals of Surgical Oncology
20. Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma?
    Axel Hauschild, Dirk Schadendorf · 2016 · The Lancet Oncology
21. Merkel Cell Polyomavirus: A New DNA Virus Associated with Human Cancer
    Margo MacDonald, Jianxin You · 2017 · Advances in experimental medicine and biology
22. Pembrolizumab and its role in relapsed/refractory classical Hodgkin’s lymphoma: evidence to date and clinical utility
    Polina Shindiapina, Lapo Alinari · 2018 · Therapeutic Advances in Hematology
23. Radiotherapy for inoperable Merkel cell carcinoma: a systematic review and pooled analysis
    Parth Sudhendu Patel, Chirag Modi, Beth McClellan, Nitin Ohri · 2018 · Dermatology Practical & Conceptual
24. Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
    Anne Zaremba, Eleftheria Chorti, Finja Jockenhöfer, Saskia Bolz, Selma Sirin, Martin Glas, Jürgen Christian Becker, Selma Ugurel, Alexander Roesch, Dirk Schadendorf et al. · 2019 · Journal for ImmunoTherapy of Cancer
25. Prognostic Biomarkers for Melanoma Immunotherapy
    Chris Twitty, Laura Ann Huppert, ADIL I. DAUD · 2020 · Current Oncology Reports
26. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
    Jingjing Fan, Xiangfeng Shen, Yishu Wang, Honglan Zhou, Guolong Liu, Yulin Li, Zhi‐Xiang Xu · 2020 · Biomedicine & Pharmacotherapy
27. The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy
    Siyuan Chen, Hongyan Lai, Jingjing Zhao, Bing Chen, Yan Li, Yuchen Li, Qin Li, Qiupeng Zheng, Shenglin Huang, Xiaodong Zhu · 2021 · BMC Cancer
28. Merkel cell carcinoma of the eyelid and periocular region
    Noreen M G Walsh · 2021 · Saudi Journal of Ophthalmology
29. Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
    Thomas Odeny, Kathryn Anne Lurain, Julius Strauss, Steven P. Fling, Elad Sharon, Anna Wright, Javier Martínez‐Picado, Teresa Morán, James L. Gulley, María González‐Cao et al. · 2022 · Journal for ImmunoTherapy of Cancer
30. Surgical damage to the lymphatic system promotes tumor growth via impaired adaptive immune response
    Yoshiyuki Nakamura, Yasuhiro Fujisawa, Naoko Okiyama, Rei Watanabe, Ryota Tanaka, Yosuke Ishitsuka, Hideaki Tahara, Manabu Fujimoto · 2017 · Journal of Dermatological Science
31. Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
    Jaafar Jaafar, Eugenio Fernández, Heba Alwan, Jacques Philippé · 2018 · Endocrine Connections
32. Predictors of survival in neurometastatic Merkel cell carcinoma
    Maya Harary, Vasileios K. Kavouridis, Manisha Thakuria, Timothy Richard Smith · 2018 · European Journal of Cancer
33. Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?
    Zeina Al‐Mansour, Linda Pang, Venu Gopal Bathini · 2018 · Drugs & Aging
34. Immune Checkpoint Inhibitors–Related Cardiotoxicity
    Venu Madhav Konala, Sreedhar Adapa, Wilbert S. Aronow · 2019 · American Journal of Therapeutics
35. Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence
    Chi Peng Timothy Lai, Joe Poh-Sheng Yeong, An S. Tan, Chong Hui Clara Ong, Bernett Teck Kwong Lee, Jeffrey Chun Tatt Lim, Aye Aye Thike, Jabed Iqbal, Rebecca Alexandra Dent, Elaine Hsuen Lim et al. · 2019 · Breast Cancer Research and Treatment
36. Tailoring precision immunotherapy: coming to a clinic soon?
    Shuting Han, Timothy Wai Ho Shuen, Who-Whong Wang, Esdy Nazim, Han Chong Toh · 2020 · ESMO Open
37. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma
    Zhendong Liu, Xingbo Cheng, Bo Pang, Sen Wang, Binfeng Liu, Cao Chen, Rongjun Qian, Wenjia Liang, Yongjie Zhu, Pengxu Li et al. · 2022 · International Immunopharmacology
38. Skin carcinomas
    Piotr Lukasz Rutkowski, Witold Owczarek, Dariusz Nejc, Arkadiusz Jeziorski, Wojciech Maria Wysocki, Monika Słowińska, Monika Dudzisz‐Śledź, Piotr Wiśniewski, Hanna Koseła-Paterczyk, Dorota Kiprian et al. · 2020 · Oncology in Clinical Practice
39. Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group
    Maria Chiara Zatelli, Antongiulio Faggiano, Antonella Argentiero, Romano Danesi, Stella D’Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida et al. · 2024 · Cancer Treatment Reviews
40. Rapamycin circumvents anti PD-1 therapy resistance in colorectal cancer by reducing PD-L1 expression and optimizing the tumor microenvironment
    Menglei Jia, Zhongwen Yuan, Hang Yu, Senling Feng, Xiaoxiao Tan, Zijing Long, Yanrong Duan, Wenting Zhu, Pengke Yan · 2024 · Biomedicine & Pharmacotherapy
41. Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors
    Matthew Hiram Taylor, Aung Naing, John D. Powderly, Paul Woodard, Luke Euichul Chung, Wen Hong Lin, Hongyu Tian, Nathan O. Siemers, Hong Xiang, Rong Deng et al. · 2024 · Journal for ImmunoTherapy of Cancer
42. Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy
    Kelly Garneski Paulson, Song Youn Park, Shailender Bhatia, Daniel S. Hippe, Paul Nghiem · 2025 · Journal of the American Academy of Dermatology
43. Molecular profiling of breast and lung cancer in women with HIV reveals high tumor mutational burden
    Carolina Caro-Vegas, Catalina Ramirez, Justin Landis, Adaora A. Adimora, Howard Strickler, Audrey L. French, Igho Ofotokun, Margaret Fischl, Eric C. Seaberg, Chia-ching J. Wang et al. · 2021 · AIDS
44. The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials
    Deniz Can Güven, Bettzy Stephen, Taha Koray Şahin, İbrahim Yahya Çakır, Enes Erul, Sercan Aksoy · 2022 · Critical Reviews in Oncology/Hematology
45. Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia
    Marta Tenuta, Carla Pandozzi, Francesca Sciarra, Federica Campolo, Alain Jonathan Gelibter, Grazia Sirgiovanni, Enrico Cortesi, Andrea Lenzi, Andrea Maria Isidori, Emilia Sbardella et al. · 2023 · Cancers
46. Cutaneous infections from viral sources in solid organ transplant recipients
    Muneeb Ilyas, Nishita V. Maganty, Ashish Sharma · 2017 · Journal of Clinical Virology
47. Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences
    Howard L. Kaufman, Carla Dias Barbosa, Isabelle Guillemin, Jérémy Lambert, Lisa A. Mahnke, Murtuza F. Bharmal · 2018 · Patient
48. The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma
    Randy Christopher Bowen, Brendan M. Lawson, Nicole M. Jody, Heather D. Potter, Mark J. Lucarelli · 2019 · Ophthalmic Plastic and Reconstructive Surgery
49. Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes
    Halis Kaan Aktürk, Aaron W. Michels · 2020 · Current Opinion in Endocrinology Diabetes and Obesity
50. Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
    Maggie Yuxi Zhou, Nam Q. Bui, Marta Lohman, Matt van de Rjin, Gloria L. Hwang, Kristen Nooshin Ganjoo · 2021 · Case Reports in Oncology
51. New interpretable machine learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
    Evan Greene, Greg Finak, Leonard A. D’Amico, Nina Bhardwaj, Candice D. Church, Chihiro Morishima, Nirasha Ramchurren, Janis M. Taube, Paul Nghiem, Martin A. Cheever et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
52. Tertiary lymphoid structures in Merkel cell carcinoma facilitate naïve and central memory T-cell infiltration linked to immunotherapy response
    Nalini Srinivas, Ivelina Spassova, Kuan Cheok Lei, Jiwei Gao, María José Pino, Giovanni Giglio, Simo Kitanovski, Mazdak Dalkoohi, Elisabeth Livingstone, Ulrike Leiter et al. · 2025 · Journal for ImmunoTherapy of Cancer
53. LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition
    Claire Buchta Rosean, Erica C. Leyder, Jeneice Hamilton, Joseph J. Carter, Denise A. Galloway, David M. Koelle, Paul Nghiem, Teri Heiland · 2023 · Frontiers in Immunology
54. Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
    John J. Nemunaitis, Laura Stanbery, David Willoughby, Ernest Bognar, Scott Brun, Adam Walter, Bradley J. Monk, Rodney Paul Rocconi, Khalil Choucair, Robert Louis Coleman · 2023 · Cancers
55. Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders
    Brandon M. Huffman, Harshabad Singh, Lestat R. Ali, Nora Horick, S. Jennifer Wang, Megan T. Hoffman, Katherine A Metayer, Shayla Murray, Alexandra Bird, Thomas Adam Abrams et al. · 2024 · Journal for ImmunoTherapy of Cancer
56. Photodynamic Therapy Derived Personalized Whole Cell Tumor Vaccine Prevents Postsurgery Tumor Recurrence and Metastasis
    Chunyu Yang, Yitong Jiang, Kaixin Zhang, Xianqi Zhu, Jianlin Li, H. Yu, Jiawei Chen, Xinggui Gu, Zhihua Gan, Qingsong Yu · 2024 · Small
57. The application and mechanism of PD pathway blockade for cancer therapy
    Xing Wang, Shan Huang, Ya Zhang, Lin Zhu, Xiaoliang Wu · 2017 · Postgraduate Medical Journal
58. New perspectives in Merkel cell carcinoma
    V. del Mármol, Célèste Lebbé · 2019 · Current Opinion in Oncology
59. Second Primary Cancers in Patients with Invasive and In Situ Squamous Cell Skin Carcinoma, Kaposi Sarcoma, and Merkel Cell Carcinoma: Role for Immune Mechanisms?
    Subhayan Chattopadhyay, Akseli Hemminki, Asta Försti, Kristina Sundquist, Jan Sundquist, Kari Hemminki · 2019 · Journal of Investigative Dermatology
60. Breaking avelumab resistance with combined ipilimumab and nivolumab in metastatic Merkel cell carcinoma?
    Valerie Glutsch, Hermann Kneitz, Matthias Goebeler, Anja Gesierich, Bastian Schilling · 2019 · Annals of Oncology
61. Primary Parotid Merkel Type Small Cell Neuroendocrine Carcinoma with Oligometastasis to the Brain and Adrenal Gland: Case Report and Review of Literature
    Sympascho Young, Justin Oh, Hussam A. Bukhari, Tony Ng, Nichole Chau, Eric Tran · 2020 · Head and Neck Pathology
62. Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629
    Brett G.M. Hughes, René González Mendoza, Nicole Basset‐Séguin, Olga Vornicova, Jacob Schachter, Abhishek Joshi, Nicolás Meyer, Florent Grange, Josep Maria Piulats, Jessica Ruth Bauman et al. · 2021 · Dermatology and Therapy
63. Immune activity in Merkel cell carcinoma
    Motoki Nakamura, Akimichi Morita · 2021 · The Journal of Dermatology
64. Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting
    Shimaa Sherif, Raghvendra Mall, Hossam Almeer, Adviti Naik, Abdulaziz Al Homaid, Remy Thomas, Jessica P Roelands, Sathiya Pandi Narayanan, Mahmoud Mohamed, Shahinaz Ahmed Bedri et al. · 2022 · Journal of Translational Medicine
65. Biopsy-Proven Metastatic Merkel Cell Carcinoma to the Orbit: Case Report and Review of Literature
    Dean R. Cugley, Samuel J. Roberts-Thomson, Alan A. McNab, Zelda S Pick · 2018 · Ophthalmic Plastic and Reconstructive Surgery
66. Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma
    Jae Eun Choi, Monique Elise Verhaegen, Sahr Yazdani, Rohit Malik, Paul W. Harms, Doris Mangelberger, Jean Ching-Yi Tien, Xuhong Cao, Yuping Wang, Marcin P. Cieslik et al. · 2019 · Neoplasia
67. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity
    Abdulrazzak Zarifa, Juan Lopez‐Mattei, Nicolas L. Palaskas, Cezar Iliescu, Jean‐Bernard Durand, Peter Y. Kim · 2020 · Advances in experimental medicine and biology
68. Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer
    Reason Wilken, Maressa C. Criscito, Anna C. Pavlick, Mary L. Stevenson, John A. Carucci · 2020 · Facial Plastic Surgery
69. Decreased survival and increased recurrence in Merkel cell carcinoma significantly linked with immunosuppression
    Mary Kate Bryant, Christine Ward, Charles E. Gaber, Paula Diane Strassle, David W. Ollila, Shachar Laks · 2020 · Journal of Surgical Oncology
70. Sex Differences in Overall Survival and the Effect of Radiotherapy in Merkel Cell Carcinoma—A Retrospective Analysis of A Swedish Cohort
    Hannah Bjorn-Andtback, Viveca Björnhagen, Hao Shi, Weng‐Onn Lui, Giuseppe Valentino Masucci, Lisa Elena Esther Villabona · 2021 · Cancers
71. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options
    Laura Gehrcken, Tatjana Sauerer, Niels Schaft, Jan Dörrie · 2021 · International Journal of Molecular Sciences
72. PD‐L1 in circulating exosomes of Merkel cell carcinoma
    Anaïs Zanella, Valentin Vautrot, François Aubin, Laure Avoscan, Mahtab Samimi, Carmen Garrido, Jessica Gobbo, Charlée Nardin · 2022 · Experimental Dermatology
73. Burden of Disease, Early Diagnosis, and Treatment of Merkel Cell Carcinoma in Latin America
    Rafael Aron Schmerling, Jose Gabriel Casas, Gabriela Cinat, Fabio Ernesto Grosso Ospina, Luiza Erthal de Britto Pereira Kassuga, Jorge Luis Martínez-Tláhuel, Luis Daniel Mazzuoccolo · 2018 · Journal of Global Oncology
74. Response to comment on “Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options”
    Loren Elizabeth de la Caridad Hernandez, Noreen Mohsin, Fabio Stefano Frech, Ashley Vander Does, Isabella Dreyfuss, Marita Yaghi, Keyvan Nouri · 2022 · Dermatologic Therapy
75. Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study
    Jia Liu, Yukun Cao, Kuikui Zhu, Sheng Yao, Mei Yuan, Xiangchuang Kong, Xiaoming Liu, Yumin Li, Yue Cui, Xiaoyu Han et al. · 2022 · Quantitative Imaging in Medicine and Surgery
76. The Role of the Large T Antigen in the Molecular Pathogenesis of Merkel Cell Carcinoma
    Julia Myrda, Franziska Bremm, Niels Schaft, Jan Dörrie · 2024 · Genes
77. Comprehensive single-cell atlas of colorectal neuroendocrine tumors with liver metastases: unraveling tumor microenvironment heterogeneity between primary lesions and metastases
    Yiqiao Deng, Qichen Chen, Chengyao Guo, Jinghua Chen, Xin Li, Zhiyu Li, Yefan Zhang, Jianjun Zhao, Jian‐Guo Zhou, Jianqiang Cai et al. · 2025 · Molecular Cancer
78. Combining DNA Damage Induction with BCL-2 Inhibition to Enhance Merkel Cell Carcinoma Cytotoxicity
    Wei Liu, Nathan A. Krump, Meenhard Herlyn, Jianxin You · 2020 · Biology
79. An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response
    Todd Cory Knepper, Robyn Panchaud, Elnara Muradova, Leah S. Cohen, James A. DeCaprio, Nikhil I. Khushalani, Kenneth Yee Tsai, Andrew Scott Brohl · 2021 · Cancer Medicine
80. Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143)
    Marco Rastrelli, Paolo Del Fiore, Irene Russo, Jacopo Tartaglia, Alessandro Dal Monico, Rocco Cappellesso, Lorenzo Nicolè, Luisa Piccin, Alessio Fabozzi, Bernardo Biffoli et al. · 2021 · Frontiers in Oncology
81. T-Cell Mediated Immunity in Merkel Cell Carcinoma
    Kelsey Ouyang, David X. Zheng, George W. Agak · 2022 · Cancers
82. Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
    Lorena Incorvaia, Alessandra Dimino, Laura Algeri, Chiara Brando, Luigi Magrin, Ida De Luca, Erika Pedone, Alessandro Perez, Roberta Sciacchitano, Annalisa Bonasera et al. · 2023 · Frontiers in Oncology
83. Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists
    Yolanda D. Tseng, Smith Apisarnthanarax, Jay Justin Liao, Shailender Bhatia, Paul Nghiem, Upendra Parvathaneni · 2017 · Expert Review of Anticancer Therapy
84. Sentinel lymph node biopsy in clinically node‐negative Merkel cell carcinoma: the Westmead Hospital experience
    Lillian N. Jenkins, Julie R. Howle, Michael Veness · 2019 · ANZ Journal of Surgery
85. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
    Ming‐Huang Chen, Wen-Chi Chou, Chin‐Fu Hsiao, Shih Sheng Jiang, Hui‐Jen Tsai, Yi‐Chang Liu, Chiun Hsu, Yan‐Shen Shan, Yi‐Ping Hung, Chia-Hsun Hsich et al. · 2019 · The Oncologist
86. Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
    Glenn J. Hanna, Alec J. Kacew, Anusha R. Tanguturi, Hans Juergen Grote, Victoria Vergara, Beatrice A Brunkhorst, Guilherme Rabinowits, Manisha Thakuria, Nicole R. LeBoeuf, Christian H. Ihling et al. · 2020 · Frontiers in Medicine
87. Modular design of Bi-specific nanoplatform engaged in malignant lymphoma immunotherapy
    Chen Bai, Pengcheng Hu, Wei Zhang, Lina Song, Di Liu, Yi Chen, Ming Ma, Ning Gu, Yu Zhang · 2020 · Nanoscale
88. Robust Production of Merkel Cell Polyomavirus Oncogene Specific T Cells From Healthy Donors for Adoptive Transfer
    Sarah I. Davies, John A. Barrett, Susan C. Wong, Mark Jesse Chang, Pawel J. Muranski, Isaac Brownell · 2020 · Frontiers in Immunology
89. Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity
    Jocelyn Ollier, Thibault Kervarrec, Mahtab Samimi, Houssem Benlalam, Pascal Aumont, Régine Vivien, Antoine Touzé, Nathalie Labarrière, Henri Vié, Béatrice Clemenceau · 2018 · Cancer Immunology Immunotherapy
90. Expression of Notch 3 and Jagged 1 Is Associated With Merkel Cell Polyomavirus Status and Prognosis in Merkel Cell Carcinoma
    Lusi Oka Wardhani, Michiko Matsushita, Satoshi Kuwamoto, Daisuke Nonaka, Keiko Nagata, MASAKO KATO, Yukisato Kitamura, Kazuhiko Hayashi · 2018 · Anticancer Research
91. Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA
    Lotte Steuten, Vincent Garmo, Hemant M. Phatak, Sean D. Sullivan, Paul Nghiem, Scott David Ramsey · 2019 · Applied Health Economics and Health Policy
92. Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding
    Jong Shin, Paul J. Phelan, Ole V. Gjoerup, William W. Bachovchin, Peter A. Bullock · 2020 · Protein Expression and Purification
93. Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy
    Winnie Wing Yan Sung, James Chung Hang Chow, William Chi Shing Cho · 2020 · Expert Review of Clinical Pharmacology
94. Biomarker Analyses Investigating Disease Biology and Associations with Outcomes in the JAVELIN Merkel 200 Trial of Avelumab in Metastatic Merkel Cell Carcinoma
    Sandra P. D’Angelo, Célèste Lebbé, Paul Nghiem, Andrew Scott Brohl, Thomas Mrowiec, Trent Leslie, Sara Georges, Gülseren Güzel, Parantu K. Shah · 2024 · Clinical Cancer Research
95. Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils
    Xiaochen Wang, Maosheng Cheng, Shuang Chen, Caihua Zhang, Rongsong Ling, Shuqing Qiu, Ke Chen, Bin Zhou, Qiuli Li, Wenbin Lei et al. · 2025 · Nature Communications
96. Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine—A Systematic Review
    Amir Dayhimi, Kimia Jazi, Yasamin Bigdeli, Fatemeh Farhoudi, Mohamadreza Erfanimanesh, Mina Esmaeili, Farhad Gorjipour, Marjan Ajami, Hamidreza Pazoki–Toroudi · 2025 · Technology in Cancer Research & Treatment
97. Avelumab and Other Recent Advances in Merkel Cell Carcinoma
    Praveen K. Bommareddy, Howard L. Kaufman · 2017 · Future Oncology
98. The Effect of Time to Postoperative Radiation Therapy on Survival in Resected Merkel Cell Carcinoma
    Ashwin Shinde, Vivek Verma, Bernard L. Jones, Richard Li, Scott Glaser, Morganna Louise Freeman, Laleh Golkar Melstrom, Robert S. Kang, Upendra Parvathaneni, Badri G. Modi et al. · 2019 · American Journal of Clinical Oncology
99. Cerebral metastasis of Merkel cell carcinoma following resection with negative margins and adjuvant external beam radiation: a case report
    Alex F. Grubb, Elizabeth Hankollari · 2021 · Journal of Medical Case Reports
100. Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review
     Nathália Alves Araújo de Almeida, Camilla Rodrigues de Almeida Ribeiro, Jéssica Vasques Raposo, Vanessa Salete de Paula · 2021 · Viruses